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Cancer immunotherapy has emerged as a treatment modality, mainly as the result of dis-
coveries in the immune response regulation, including mechanisms that turn off immune
responses. Immunogenic cutaneous melanoma is a canonical model for therapeutic
immunotherapy studies. “Passive” immunotherapy with monoclonal antibodies (mAbs)
has outpaced “active” immunotherapy with anti-tumor vaccines, and mAbs that antagonize
the off responses have been recently introduced in clinical practice. Despite these recent
successes, many unresolved practical and theoretical questions remain. Notably unknown
are the identity of the lymphocytes that eliminate tumor cells, which white cells enter
into tumors, through which endothelium, in what order, and how they perform their task.
The parameters of size and location that could be used to determine in which tumors the
immune response may be sufficient to eradicate the tumor are yet unknown. Immunother-
apy has been so far more efficient to treat solid and hematologic tumors located outside
the central nervous system, than primary brain tumors and brain metastases. In contrast
to recent advances with mAbs, anti-tumor vaccine development has been lagging behind.
The multiplicity of antigens that must be targeted to achieve significant clinical response is
partially responsible for this lag, especially in melanoma, one of the most mutated tumors.
Further hampering vaccination results is the fact that tumor elimination by the immune sys-
tem is the result of a race between tumors with different growth rates and the relatively
slow development of the adaptive immune response. The enhancement of the native arm
of the immune response or the administration of targeted chemotherapy to slow tumor
development, are approaches that should be studied. Finally, criteria used to analyze patient
response to immunotherapeutic treatments must be perfected, and the patient populations
that could benefit the most from this approach must be better defined.
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INTRODUCTION
After decades of cautious approach, immunotherapy has arrived
as a cancer treatment. This is best demonstrated by the thera-
peutic benefit conferred by monoclonal antibodies (mAbs) tar-
geting the immune checkpoints CTLA-4/CD80/CD86 and PD-
1/PD-L1 in metastatic cutaneous melanoma (CM). Anti-tumor
effects are accompanied by autoimmunity, an affordable price
for the clinical responses obtained. However, there is still room
for improvement of this therapeutic approach. Important ques-
tions still remain, which, if adequately answered, may foster this
new field. In this review, we continue our previous discussion
(1), and delve into several such points. We shall review, although
not exhaustively, some recent findings about the immunoreg-
ulatory molecules CTLA-4 and PD-1, with special emphasis
on their role in CM. We shall also review the most impor-
tant clinical trials performed with their respective mAbs. In the
course of this review, we shall address several important points,
such as:
(1) Is the presence of lymphocytic infiltrate in human tumors
necessary prior to anti-CTLA-4 or anti-PD-1 mAb adminis-
tration?
(2) What are the mechanisms that activate CD8+ lymphocytes
as putative effectors of the clinical response obtained in CM
patients?
(3) What are the specificities of these anti-tumor lymphocytes?
(4) What mechanisms do lymphocytes use to enter tumors, and
how can they be improved?
(5) Can tumor lymphocytic infiltrate be increased by prior
vaccination?
CTLA-4: BASIC KNOWLEDGE
Cytotoxic T-lymphocyte antigen-4, CTLA-4 (CD152), is a type
I transmembrane glycoprotein that presents homology to CD28
and down-regulates T-cell activation, playing a key role in the
regulation of immune homeostasis. CTLA-4 surface expression is
induced in activated effector T cells (Teff cells) (2). It is constitu-
tively expressed in high levels in CD4+CD25+ regulatory T cells
(Treg cells) (3) and binds with higher affinity than CD28 to the
costimulatory molecules CD80 (B7.1) and CD86 (B7.2) expressed
by antigen-presenting cells (APC). Different humanized mAbs tar-
geting CTLA-4 have been developed, among them are Ipilimumab,
an IgG1 mAb, and Tremelimumab, an IgG2a mAb.
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Although anti-CTLA-4 Ipilimumab has been approved for use
in metastatic CM patients, as it leads to improved overall survival
(OS), its mechanisms of action are not completely understood.
Whether anti-CTLA-4 antibody acts directly in cis on the Teff
cell compartment, by blocking inhibitory signals without cellular
interaction with other lymphocytes (4, 5), or if it behaves indi-
rectly in trans, through Treg cell depletion or limitation of their
immunosuppressive function (6), is not yet clear. Pre-clinical stud-
ies in the B16/BL6 murine melanoma model have demonstrated
that the Gvax plus anti-CTLA-4 blockade increased the num-
ber of tumor-infiltrating lymphocytes (TILs), attaining 1.4× 106
TIL per gram of tumor tissue (approximately 109 tumor cells)
(7), though it is difficult to explain how this effector/target ratio
(1/1000) could achieve tumor regression. Curran et al. demon-
strated in the same experimental model that treatment with anti-
CTLA-4 or anti-PD-1 increased the CD8+ Teff/Treg ratio around
10-fold, that the effector/tumor-cell ratio was about 1–2/1000,
and that only when both mAbs were combined with a cellular
vaccine, cures were observed (8). In a murine prostate cancer
model, Waitz et al. observed that cryoablation of tumors plus anti-
CTLA-4 increased the CD8+ and CD4+ infiltration of secondary
tumors, attaining infiltration of 1 CD4+ and CD8+ lympho-
cyte per 1000 tumor cells (9). These results could be achieved
by cis and/or trans mechanisms. However, other work in the
B16/BL6 murine melanoma model by Simpson et al. reported a
previously undescribed mechanism of action for the anti-CTLA-4
mAb, which involved an antibody-dependent cellular cytotoxi-
city (ADCC)-mediated depletion of intra-tumoral Treg cells by
FcRIV-expressing macrophages. This would lead to an increase
in the intra-tumoral Teff/Treg ratio (10) and suggested a pre-
dominant trans mechanism. Recent pre-clinical studies highlight
the roles of Fcγ receptors (FcγR) and the tumor microenviron-
ment in the activity of different immunomodulatory antibodies
(11), including anti-CTLA-4. The ADCC-mediated mAb effect was
also described for an anti-GITR antibody (GITR: glucocorticoid-
induced TNFR-related protein) (12) and for an anti-OX40 anti-
body (13). Consistent with these observations, different anti-
tumoral efficiencies were detected between different anti-CTLA-4
antibody isotypes in mouse models, the most efficient being IgG2a,
a strong binder of activating FcγR (14). However, if ADCC was
the mechanism of action of Treg cell lysis, it is unclear why
CD8+ lymphocytes were not also depleted, although, Treg cells
express higher levels of CTLA-4. Pointing to a concurrent cis
mechanism of action, experimental evidence in CTLA-4−/− mice
carrying human CTLA-4 suggested that anti-CTLA-4 mAb would
need to bind to both Teff and Treg cells to produce full tumor
protection (15).
Turning now to the human setting, if a favorable balance of the
Teff/Treg ratio appears necessary to induce anti-tumor responses,
a relevant matter is how important is the actual number of
intra-tumoral lymphocytes before and after therapy, and if the
lymphocytic infiltrates are within the tumor (brisk) or peripheral
(non-brisk). With respect to the lymphocytes present before ther-
apy, the question is best addressed in primary tumors and visceral
metastases, since lymphocytes-infiltrating lymph node metastases
are difficult to differentiate from residing lymphocytes, hence their
name tumor-associated lymphocytes (TAL) (16). Whereas the
presence of TIL in primary tumors with a Breslow index between
1.7 and 6.0 mm is associated with better prognosis, the prognos-
tic evidence regarding the presence of TIL in metastases is less
clear [see Oble et al. for a review (17)]. Hakansson et al. have
performed fine-needle-aspiration in CM metastatic patients and
observed that metastasis with>2% CD4+ lymphocytes responded
better to biochemotherapy than patients with <2% CD4+ lym-
phocytes (18). Anyhow, the number of lymphocytes relative to
tumor cells appears to be low (around 1/103), especially if one
takes into account the low affinity of the TCR/MHC I-peptide
complex (10−4–10−5 M) and that the estimated number of lytic
cycles per cytotoxic T-lymphocyte is low (19). Therefore, it is prob-
able that the number of “spontaneously occurring” lymphocytes
in a tumor should be dramatically augmented to attain a mean-
ingful clinical response. A possible factor that could augment TIL
within tumors derives from reports suggesting that CTLA-4 block-
ade increases T-cell motility (20–22). In a study using intravital
microscopy in the mouse model B16/BL6, Pentcheva-Hoang et al.
analyzed the motility of reporter pmel-1 T cells and reported that
chronic anti-CTLA-4 treatment increased pmel-1 T-cell velocity
in tumors and in tumor-draining lymph nodes, whereas acute
CTLA-4 blockade increased pmel-1 T-cell velocity exclusively in
tumor-draining lymph nodes (22). Whether this phenomenon
actually favors the immune response is subject to debate. Increased
T-cell motility could favor T-cell scanning, mobilize T cells from
unproductive interactions with APC, and increase T-cell infiltra-
tion into tumors, which would be extremely advantageous. On
the other hand, increased T-cell motility could be detrimental to
the immune response by preventing efficient TCR–MHC-IAPC or
TCR–MHC-Itumor cell interactions. In the clinic, a direct corre-
lation between lymphocytic infiltration and prognosis has not
been clearly established. The quantitative distinction between
brisk lymphocytic infiltrates, which would be capable of cytolytic
activity, and peripheral infiltrates, which would act as a dissemi-
nation barrier, is generally not described. The analysis of biopsies
of metastatic CM lesions before and after Gvax and Ipilimumab
treatment, showed low numbers of CD8+ and Treg lymphocytes
in pre-treatment biopsies and dense CD8+ cell infiltration after
treatment. However, the low number of infiltrating Treg cells
would suggest that intra-tumoral Treg cell lysis is not the main
target of Ipilimumab. However, tumor necrosis did correlate with
higher infiltrating CD8+ T/Treg cell ratios (23). Evidence from
bladder and prostate cancer patients also suggests that anti-CTLA-
4 treatment leads to an increased intra-tumoral Teff/Treg ratio (24,
25). The origin of the CD8+ lymphocytes that infiltrate tumors
is uncertain. CD8+ cells could derive from the CTLA-4 blockade
in central lymphoid organs in cancer patients, since it could pro-
mote T-cell proliferation and lead to increased T-cell infiltration
in most patients (26, 27). CTLA-4 blockade with Tremelimumab
led to a diversification of the peripheral TCR repertoire (28), an
observation that was reiterated in a separate study in patients
treated with Ipilimumab (29). Additionally, the maintenance of
high frequency TCR clones was associated with improved clinical
outcome. Recent evidence by Kvistborg et al. suggests that CTLA-
4 blockade broadens CM-specific T-cell response (30). These
authors analyzed HLA-A*0201-restricted epitope recognition by
CD8+ T cells in CM patients before and after Ipilimumab, and
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reported that anti-CTLA-4 induced CD8+ T-cell clones absent
before treatment, although pre-existing clones were not signifi-
cantly boosted. However, not every intra-tumoral CD8+ cell was
functional or directed against tumor antigens, since tumor infil-
tration by T cells in patients treated with Tremelimumab did not
correlate with clinical responses (27). This suggests that resistance
to CTLA-4 blockade could depend on other immunosuppressive
mechanisms displayed by the tumor. Thus, the current under-
standing is as follows: experimental data suggest that successful
anti-CTLA-4 treatment would require abundant Treg cells, CD8+
lymphocytes, and NK cells and/or macrophages within the tumor;
although it is not yet known in what quantity or if they should be
present as brisk or peritumoral infiltrates. It is likely that CD8+
lymphocytes will need to be expanded by treatment, although the
optimal time span is unknown. Once Ipilimumab is administered,
there are two main possibilities: (i) CD8+ cell proliferation would
take place in lymphoid organs, and higher numbers of CD8+
cells with increased motility would migrate into tumors; (ii) Ipili-
mumab would mediate the ADCC of Treg cells through the FcγR
of residing macrophages and/or NK cells; CD8+ cells would be
relieved from Treg cell downregulation, and would kill tumor
cells. However, the latter possibility does not take into account
that the number of Treg cells, CD8+ lymphocytes, macrophages,
and NK cells in many metastases are insufficient before treatment
begins (18).
CLINICAL RESPONSE TO ANTI-CTLA-4 TREATMENT
In a randomized Phase III trial for 676 HLA-A*0201 CM patients
with unresectable Stage III or Stage IV disease (31), previously
treated patients and whose disease had recurred, received, in a
3:1:1 ratio, Ipilimumab (3 mg/kg every 3 weeks for a total of four
doses) plus gp100 peptide vaccine (403 patients); Ipilimumab
alone (137 patients); or gp100 alone (136 patients). Around 60%
of patients treated with Ipilimumab presented immune-related
adverse events (irAE), mainly gastrointestinal (diarrhea, colitis),
dermatologic (pruritus, rash), and endocrine (hypothyroidism,
hypopituitarism); 10–15% were grade 3–4 toxicities. The median
OS for the three patient groups were 10.0, 10.1, and 6.4 months,
respectively. A 3.5-month gain in OS was obtained with Ipili-
mumab, and the drug was approved for the treatment of metastatic
CM (Table 1). The gp100 vaccine was composed of two gp100 pep-
tides, 209–217 and 280–288, in four doses of 1 mg each, emulsified
Table 1 | Selected clinical trials with anti-checkpoint mAbs.
Patients Phase Treatment n Study groups Results Toxicity Reference
ANTI-CTLA-4
Melanoma
HLA-A*0201-positive
unresectable stage III or IV
previously treated
III Ipilimumab 676 Ipilimumab plus gp100 OS 10.0 months groups
I versus 10.1 months
group II versus
6.4 months group III
10–15% irAE
grades 3–4
(31)
gp100 vaccine Ipilimumab
gp100
Melanoma unresectable
stage III or IV previously
untreated
III Ipilimumab
DTIC
502 Ipilimumab (10 mg/kg i.v.)
plus DTIC (850 mg/m2)
DTIC (850 mg/m2) plus
placebo
OS 11.2 months group I
versus 9.1 months
group II
56.3% grades
3–4 group I,
27.5% grades
3–4 group II
(33)
ANTI-PD-1
Melanoma unresectable
stage III or IV
Ib Lambrolizumab 135 10 mg/kg every 2–3 week OR 38% 13% grades 3–4
irAEs
(34)
2 mg/kg every 3 week
Melanoma unresectable
stage III or IV BRAF wild-type
previously untreated
III Nivolumab
DTIC
418 Nivolumab 3 mg/kg every
2 week
DTIC 1000 mg/m2 every
3 week
OS (1 year) 72.9%
group I versus 42.1%
group II
11.7% grades
3–4 group I,
17.6% grades
3–4 group II
(35)
Refractory or relapsed
Hodgkin’s lymphoma
pre-treated
I Nivolumab 23 1–3 mg/kg dose escalation
cohort, expansion cohort
3 mg/kg 1, 4 weeks and
then every 2 week
OR 87%, PR 70%, CR
17%
22% grade 3 (36)
Advanced melanoma, NSCLC,
prostate cancer, renal-cell
cancer, CRC
I Nivolumab 296 1, 3, and 10 mg/kg OR 18–28% 14% grades 3–4 (37)
ANTI-CTLA-4+ANTI-PD-1
Melanoma unresectable
stage III or IV previously
treated with Ipilimumab
I Nivolumab
Ipilimumab
53 Concurrent regimen OR 40% 53% grades 3
or 4
(38)
irAEs, immune-related adverse events; OS, overall survival; OR, overall response; CR, complete response; PR, partial response.
www.frontiersin.org March 2015 | Volume 6 | Article 127 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Madorsky Rowdo et al. Tumor and immunity combat
in Montanide ISA-51. Because two of the study arms administered
gp100 peptides that are presented by the HLA-A*0201 haplotype,
this study was performed exclusively on HLA-A*0201 patients.
Whether HLA status was relevant to Ipilimumab efficacy remained
unanswered, until a retrospective analysis of Ipilimumab efficacy
in populations with HLA-A*0201-positive and negative haplo-
types yielded similar clinical results (32). These results strongly
suggest that CD8+ lymphocytes are active against melanoma cells,
regardless of HLA-A*0201 haplotype.
Another randomized Phase III Ipilimumab study was per-
formed for 502 patients with previously untreated metastatic CM.
Ipilimumab in combination with dacarbazine (DTIC) was com-
pared to DTIC plus placebo; the median OS in the first group
was 11.2 versus 9.1 months in the DTIC plus placebo group (33)
(Table 1). Remarkably, Ipilimumab treatment may take months
to induce tumor remission, indicating that it acts by different
mechanisms of action than most chemotherapeutic agents.
Prior to Ipilimumab approval by the FDA,an anti-CTLA-4 IgG2
mAb (Tremelimumab) was developed by Pfizer (CP-675,026) and
assayed in a Phase I clinical trial on 39 patients, of whom 29 had
CM, in doses ranging between 0.01 and 15.0 mg/kg. The primary
toxicities were dermatitis and diarrhea (39). In that trial, 2/29
CM patients had partial responses (PRs) and 2/29 had complete
responses (CRs). The evidence remains unclear as to the mecha-
nism of anti-tumor action of Tremelimumab. It should be taken
into account that the interpretation of results is often complicated
by differences in biopsy timing. Thus, in a report of a Phase I trial
of mAb CP-675,026 (39), immunohistochemical (IHC) analysis
of a residual tumor mass after treatment revealed inflammatory
infiltration by CD15-positive macrophages, but no CD3+ lym-
phocyte infiltration, perhaps suggesting that a long-term response
may also involve macrophages. Huang et al. (27) demonstrated in
a Phase II study, which compared paired biopsies before and after
treatment that 14/18 evaluable CM patients treated with Treme-
limumab had increased CD8+ lymphocyte infiltration, but this
infiltration was not correlated with clinical responses. Instead, they
found an increase of Treg cells in responding patients. It is inter-
esting to note that in that study, intra-tumoral CD8+/Ki67+ cells
were scarce, even in a patient with CR, suggesting that the CD8+
pool expansion took place outside the tumor. A Phase III ran-
domized trial (A3671009) comparing Tremelimumab with DTIC
in 630 CM patients was halted in 2008 because Tremelimumab
failed to improve DTIC outcomes. The discrepancy between the
results for Ipilimumab and Tremelimumab is difficult to explain;
possible reasons are the different affinities of mAbs for CTLA-4, or
the different isotypes of the mAbs utilized, IgG1 and IgG2a, respec-
tively, since they have different capacities for binding complement
and FcγR (40).
So far, the activity of anti-checkpoint mAbs has been detected
in peripheral tumors. The possible activity of these agents in pri-
mary brain tumors is largely unexplored, one of the predicted
obstacles being the poor permeation of circulating blood cells
and large molecules through the hematoencephalic barrier. With
respect to brain metastases of several tumors, which constitute a
huge medical problem, in most clinical trials using anti-checkpoint
mAbs, patients with brain metastases have been excluded. Nev-
ertheless, the activity of Ipilimumab in 72 melanoma patients
with brain metastases was assayed in an open-label, Phase II trial
(41). The results suggested that Ipilimumab may have some activ-
ity in patients with small, asymptomatic metastases. Due to the
large number of tumors that metastasize into the central nervous
system, this field deserves increased attention.
In conclusion, Ipilimumab appears to act on tumor cells indi-
rectly, through the activation of the immune system, a mechanism
of action consistent with the irAE observed. As to the relevant
antigens that mediate tumor regression, the fact that gp100 vac-
cine added no benefit to Ipilimumab is not surprising, since Aris
et al. reported that in most CM, almost half of proliferating cells do
not express melanocyte differentiation antigens (MDAs), and that
MDA expression has considerable plasticity (42). Also, Chandran
et al. recently found that isolation of CTL clones specific to MART-
1 and gp100, although exerting powerful cytolytic activity in vitro,
did not induce important remissions when injected to melanoma
patients (43). In an interesting turnabout, Snyder et al. recently
reported the results of an exomic analysis of responder versus non-
responder patients treated with Ipilimumab and Tremelimumab
(44). They found that the high mutation frequency in CM (0.5–
>100 mutations per megabase) creates neoantigens with epitopes
similar to “foreign,” probably infectious, epitopes. That epitopic
similarity would determine that Teff lymphocytes directed against
those foreign epitopes would then be able to recognize mutated
tumor antigens. Therefore, higher mutation frequencies could be a
favorable condition, although not determinant, for a good clinical
response in anti-immune checkpoint mAb therapy. In an exper-
imental murine model of a highly mutated methylcholanthrene-
induced sarcoma, Gubin et al. have also found specific mutations
that generate neoepitopes, which may be identified and used to
generate long peptidic vaccines that alone or combined with anti-
bodies anti-checkpoint CTLA-4 and/or PD-1 could afford tumor
protection and elimination (45).
THE BIOLOGY OF THE PD-1 PATHWAY
The programed cell death protein-1, PD-1 (CD279), is an
inhibitory receptor of the extended CD28 family of T-cell reg-
ulators. Besides being expressed in activated T cells, PD-1 is
also expressed in B cells and monocytes. PD-1 binds PD-L1
(B7-H1/CD274) (46) and PD-L2 (B7-H2/CD273) (47). PD-L1 is
expressed in T cells, B cells, macrophages, dendritic cells (DCs),
and some non-immune cells, and is upregulated after activation.
PD-L2 is more tightly regulated and is primarily expressed on
activated macrophages and DCs. PD-1 is expressed on the surface
membrane of activated T cells, and its main role is to limit autoim-
munity and T-cell activity in peripheral tissues during an inflam-
matory response to infection (48–50). T-cell activation induces
PD-1 expression, and PD-L1 binding leads to the inhibition of T-
cell activation and effector function. This inhibition is mediated
by the recruitment of phosphatases to the immune synapsis that
dephosphorylate molecules related to TCR signaling (51).
PD-L1 is not detectable in most normal, non-inflamed tissues
(52–54), but is highly expressed in several human tumors includ-
ing CM (55). Since it is minimally expressed in the adjacent normal
tissue, it has been suggested that PD-L1 has a role in attenuating
anti-tumor immune responses (52, 53). IFN I and II upregulate
PD-L1 expression by tumor cells (52, 56), thus promoting the
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apoptosis of antigen-specific T cells in vitro, and it has also been
suggested in a murine model that PD-L1+ tumors deleted acti-
vated T cells in vivo (52). Additionally, PD-L1 has been implicated
in tumoral antiapoptotic activity, and both mechanisms would
favor tumor development (57–59). In addition to PD-L1/PD-1
recognition, an unexpected PD-L1/CD80 interaction was detected
(60), whereby CD80 expressed on T cells took on a receptor role
and delivered inhibitory signals in response to PD-L1 binding (61,
62). In CM, PD-L1 expression was correlated with TILs (63–65).
Taube et al. observed that 98% of PD-L1+ tumors were associated
with TILs. They proposed that TILs trigger their own inhibition
by secreting IFN-γ, among other cytokines, that drive tumor PD-
L1 expression (63). Clinically, PD-L1 expression levels on tumors
correlate with poor clinical outcome for patients with several types
of cancer, including CM (66–71).
In a murine model, PD-1 was highly expressed on Treg cells and
promoted their function and proliferation in the presence of the
ligand (72). As many tumors are infiltrated or surrounded by host
immune suppressor Treg cells, blockade of PD-1 may upmodulate
anti-tumor immune response by decreasing intra-tumoral Treg
cell number or action (73). Comparing the two inhibitory recep-
tors described in this review, PD-1 acts in the peripheral tissues
and in tumors, regulating effector T-cell activity, whereas CTLA-4
acts in the lymph nodes, regulating T-cell activation (73). The nar-
row therapeutic window for anti-CTLA-4 therapy can be partially
attributed to the fact that CTLA-4 ligands are not expressed in
tumor cells. Contrarily, PD-L1/PD-1 would interact selectively in
the tumor microenvironment (63).
All of the previously mentioned data strongly support a central
role for PD-1 and/or its ligands in tumor immune escape. Several
mAbs were developed against PD-1: (a) Nivolumab, also known
as BMS-936558 or ONO-4538; (b) Pembrolizumab formerly Lam-
brolizumab, also known as MK-3475; (c) Pidilizumab (CT-011);
and anti-PD-L1 (BMS-936559; MEDI4736; MPDL33280A). PD-
1 blockade has been shown to enhance T-cell responses and
presented anti-tumoral activity in pre-clinical models (52, 57, 74).
CLINICAL RESPONSES TO ANTI-PD-1 AND ANTI-PD-L1
TREATMENTS
BMS-936558/Nivolumab is a fully humanized mAb, IgG4 (kappa)
that binds PD-1. Nivolumab was assayed in a Phase I trial involv-
ing 296 patients with advanced solid tumors: CM, non-small-cell
lung cancer, castration-resistant prostate cancer, renal-cell cancer,
and colorectal cancer. The doses assayed varied between 0.1 and
10.0 mg/kg i.v., every 2 weeks, for periods lasting more than 1 year.
PD-L1 expression was assessed by IHC, and tumors with >5%
cells with membrane-expressed PD-L1 in any lesion were deemed
positive. Of the 106 patients with CM, 26 objective responses
(ORs) (24.5%) were observed, many of which achieved stable dis-
ease. When tumors were stratified according to PD-L1 status, 36%
OR were observed in PD-L1-positive patients versus 0% OR in
PD-L1-negative patients. Thus, PD-L1 expression levels would
appear to be a good predictive marker for anti-PD-1 therapy.
The adverse events reported for this study was about 41%, 6%
being grade 3 or 4 serious adverse events (37). Recently, Robert
et al. reported the results of a Phase III clinical study in which
Nivolumab (3 mg/kg every 2 weeks) or DTIC (1000 mg/m2 every
3 weeks) were administered to 418 previously untreated patients
with stage III or stage IV unresectable, BRAF wild-type, tumors. At
1 year, the OS was 72.9% for the Nivolumab group versus 42.1%
for the DTIC group; the median progression-free survival was
5.1 months for Nivolumab versus 2.2 months for the DTIC group,
and the overall response rate was 40.0% for Nivolumab versus
13.9% for the DTIC group (35) (Table 1). In this study, PD-L1
was determined prospectively and was considered positive if >5%
of at least 100 cells in any histological section had positive mem-
brane staining. The CR rate was 7.6% in the Nivolumab group
versus 1.0% in the DTIC group. In contrast to previous results
from this mAb, the status of PD-L1 did not affect the response to
Nivolumab.
Hamid et al. reported the results of a Phase I clinical study with
another anti-PD-1 mAb, Lambrolizumab/Pembrolizumab (MK-
3475, Merck Sharp and Dome) on 135 patients with advanced CM,
half of whom had received prior Ipilimumab treatment (Table 1).
Lambrolizumab is an IgG4 humanized mAb, whose variable region
derives from a high-affinity murine mAb (dissociation constant:
29 pM). The doses utilized were 2 or 10 mg/kg, every 2–3 weeks;
the half-life of serum mAb was 2–3 weeks. The response rate was
38% and the overall median progression-free survival among the
135 patients was longer than 7 months. Toxic effects were observed
in 79% of the patients, but only 13% were grade 3 or 4 toxicities.
Patients were not selected on the basis of PD-L1 expression by
tumor cells (34). Retrospective analysis of PD-L1 expression was
performed in this group of patients; PD-L1-positive patients had
a 53% response rate whereas only 6% PD-L1-negative patients
responded (P = 0.004). However, durable clinical responses were
observed in both PD-L1 positive and negative patients (75).
This study also supports a correlation between PD-L1 expression
and response to anti-PD-1, although the lower limit of PD-L1
expression was set to 1% of tumoral or stromal cells (see below).
Another study aimed to inhibit PD-L1 through the adminis-
tration of BMS-936559, a humanized IgG4 mAb that binds PD-L1
and inhibits its binding to PD-1 and CD80. In this Phase I clinical
study, BMS-936559 was administered to patients with a variety of
solid tumors at doses ranging from 0.3 to 10 mg/kg, every 2 weeks,
in 6-week cycles. ORs ranged from 6 to 17% in different tumors,
and prolonged stabilization of the disease was observed in 12–41%
of the patients at 24 weeks (76).
A combination of Nivolumab and Ipilimumab was also assayed
in CM patients (38), and attained an OR rate of 50%. PD-L1 levels
in tumor cells were measured and deemed positive when ≥5% of
at least 100 tumor cells were positive in any section. In this study,
no relationship was found between the level of PD-L1 expression
and the responses obtained.
In conclusion, the relationship between PD-L1 expression and
the efficacy of the anti-PD-1 mAbs is still unclear. Studies have used
different techniques to measure PD-L1: (i) some of them include
normal stromal cells in the criteria of positivity, whereas others
only measure tumor cells; (ii) some groups fix a lower threshold
for PD-L1 positivity at 1% (75), and others at 5% (37, 38). Some
studies found a relationship between PD-L1 positivity and clinical
response (37, 75), and others have not (35, 38). Furthermore, the
precise mechanism of action of anti-PD-1 mAbs is unclear. It is
difficult to visualize how the 1–5% of cells that are positive could
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trigger CD8+ cell reactivity toward the whole tumor by blocking
PD-L1/PD-1 interaction with anti-PD-1 mAbs; one would have
to assume an “immunological chain reaction” that has not yet
been described. Secondly, Nivolumab and Lambrolizumab were
designed with an IgG4 isotype to avoid complement or ADCC-
mediated lysis of CD8+ cells and the probability of cytokine
release syndrome. This would imply that intra-tumoral Treg cells
remain unaffected and conflicts with the experimental evidence
obtained with anti-CTLA-4 mAbs that demonstrated that elimina-
tion of Treg cells was necessary for CD8+ expansion and activity.
Four patterns of clinical response have been described in studies
using anti-CTLA-4 and anti-PD-1 mAbs: (1) response in baseline
lesions by week 12; (2) stable disease with response in some lesions;
(3) responses after an increase in the size of some lesions, and (4)
reduction of total tumor burden after week 12, with the appear-
ance of new tumor lesions early on (77). We have not found any
data describing the cellular composition of the tumor lesions that
grew before attaining clinical response. Is it pure tumor growth,
or is the increase in size due to tumor infiltration by lymphocytes
with inflammation and edema?
Furthermore, the origin of the CD8+ lymphocytes that are
presumably the effector cells of the anti-CTLA-4 and anti-PD-1
mAb has yet to be determined. In a paper by Huang et al., only
scarce intra-tumoral CD8+/Ki67+ lymphocytes were observed in
some Tremelimumab-responder patients, suggesting that expan-
sion of the CD8+ pool took place outside the tumor itself (27).
However, Tumeh et al. recently reported that the best predictors
for response to anti-PD-1 treatment is a high concentration of
CD8+ lymphocytes at the growing border of tumors coexisting
with PD-L1 expression by tumor cells; blocking the interaction
of the PD-1/PD-L1 axis would trigger IFN-γ release and further
expansion of CD8+ lymphocytes within the tumor (78).
Regarding the efficacy of anti-PD-1 mAbs in other tumors,
Hodgkin’s lymphoma consists of tumor Reed–Sternberg cells sur-
rounded by an inflammatory infiltrate; tumor cells have an ampli-
fication of 9p-24.1 region harboring PD-L1 and PD-L2 loci. Recent
results of a Phase I trial on patients with relapsed or refractory
Hodgkin’s lymphoma suggest that Nivolumab may be useful, since
87% of the patients achieved CR (17%) or PR (70%) (36). Analy-
sis of Reed–Sternberg cells in pre-treatment biopsies indicated
a gain in copy numbers of PD-L1 and PD-L2 ligands. In this
study, PD-1 expression by infiltrating T cells was of low intensity,
which has been postulated as a favorable predictor to anti-PD-1
treatment (79).
A schema depicting the mechanism of action of anti-
checkpoint mAbs is shown in Figure 1.
CANCER VACCINES
Although anti-CTLA-4 and anti-PD-1 mAbs demonstrated
remarkable anti-tumor activity in advanced CM patients, attain-
ing overall response rates between 40 and 50%, the fact that CR
are a few percent indicates that this therapeutic approach needs
improvement. It is possible that the generally scarce CD4+ and
CD8+ tumor infiltration could hamper mAb efficacy. In that case,
the therapeutic activity of mAbs targeting immune checkpoints
could be enhanced by an increase in lymphocytic infiltration
before treatment. One possible strategy for this increase is to
employ anti-tumor vaccines in the adjuvant setting. For several
reasons, though mainly due to the heterogeneity and mutability
of CM, we believe that the use of monoantigens as vaccines is
doomed to failure. We have developed instead a strategy using the
mini-allograft vaccine CSF-470 composed of four lethally irradi-
ated allogeneic CM cell lines combined with BCG and soluble
rhGM-CSF as adjuvants. The danger signals provided by allo-
geneic HLA, BCG, and GM-CSF force the migration of APC and
macrophages to the vaccination site, where they would phago-
cyte tumor antigens, present them in an adequate HLA setting
to naïve lymphocytes, either in situ or upon migration to the
draining lymph nodes. This mini-allograft has been assayed in
Phase I clinical trials (80, 81) and is currently being tested against
medium-dose IFN-α2b as a post-surgical adjuvant therapy in
stages IIB-III CM patients (randomized CASVAC-0401 phase II/III
trial; clinicaltrials.gov NCT01729663). Occasional tumor biopsies
of recurrent CM showed brisk lymphoid infiltration, mainly com-
posed of CD8+, CD4+, and CD20+ lymphocytes with few Treg
cells, and striking evidence of tumor-cell killing by CD8+ and
CD4+ lymphocytes (82). Six months after vaccination began,
circulating NK cells were significantly increased (83). It will be
interesting to assess whether prior vaccination with the allogeneic
vaccine CSF-470 improves the efficacy of mAbs targeting immune
checkpoints.
TUMOR VESSELS AND LYMPHOCYTE INFILTRATION
As previously described, much of the activity related to
immunotherapy and cancer takes place within tumors, through
the action of a variety of immune cells. However, the factors that
govern the arrival of these effectors into tumors remain poorly
understood. In recent years, growing evidence shows that sev-
eral redundant regulatory mechanisms simultaneously produce an
immunosuppressive tumor microenvironment, which may limit
the effectiveness of immunotherapies and lead to ineffective or
suboptimal responses. The limited ability of activated lympho-
cytes to infiltrate the tumor remains a fundamental problem (84).
The tumor vasculature itself, due to numerous structural and
functional abnormalities, can represent a great barrier for a suc-
cessful T-cell tumor infiltration (85, 86). Unlike normal vessels,
tumor blood vessels show heterogeneous distribution, tortuos-
ity, dilatation, and fragility; this results in leaky tumor vessels,
higher interstitial pressure, heterogeneous permeability, and irreg-
ular blood flow (87, 88). The ensuing tumor microenvironment,
characterized by interstitial hypertension, hypoxia, and acidosis,
may undermine immune cell trafficking, proliferation, and func-
tion within the tumor (89). Abnormalities in tumor vasculature
result from the imbalance between pro- and anti-angiogenic fac-
tors. Angiogenic factors such as vascular endothelial cell growth
factors (VEGFs),not only suppress the maturation of DCs (90) and
trigger Treg cell proliferation (91), but also inhibit leukocyte–vessel
wall interactions by down-regulating vascular adhesion molecules,
such as intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1), E-selectin, and CD34 (92–94);
this phenomenon has been defined as “endothelial cell (EC)-
anergy.” Thus, the Teff cells circulating in tumor vessels can hardly
interact with ECs, roll through the vascular endothelium, and
extravasate into the tumor. Recently, Voron et al. have suggested
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FIGURE 1 | Anti-checkpoint therapies targeting CTLA-4 or PD-1.
Peripheral CD8 infiltration (left) become tumor invasive (right) after
anti-checkpoint treatment. (A) CD8+T cells are inhibited by CTLA-4
signaling and by Treg cells. mAbs anti-CTLA-4 interrupt negative
signaling resulting in CD8+ cells proliferation. (B) PD-1 expressed in
CD8+ cells interacts with PD-L1 expressed in tumor cells and leads to
CD8+ inhibition. mAbs anti-PD-1 disrupt negative regulation resulting
in activation of CD8+ cells.
another immunosuppressive property for VEGF. They proposed
that the release of VEGF-A by the tumor enhances the expres-
sion of inhibitory immune checkpoint molecules (PD-1, Tim-3,
CTLA-4, and Lag-3) on activated CD8+ T cells in tumors (95).
Anti-angiogenic therapies can “normalize” many of the struc-
tural and functional abnormalities of tumor vasculature, decreas-
ing interstitial fluid pressure, increasing oxygenation, and improv-
ing drug penetration into tumors (88). Therefore, the combination
of anti-angiogenic drugs with cytotoxic chemotherapy or radio-
therapy may ameliorate the final outcome (88, 96). Moreover, pre-
clinical studies have suggested that anti-angiogenic therapy could
increase tumor-infiltrating T-cell numbers (97–100). In murine
models, Li et al. demonstrated that VEGF blockade (by expression
of a soluble chimeric VEGF receptor – sVEGFR1/R2) improved
the efficacy of a GM-CSF-secreting tumor-cell immunother-
apy. They observed a correlation between prolonged survival
and a significant increase in the number of activated CD4+
and CD8+ TILs, as well as enhanced apoptosis of Treg cells,
which modified the Treg/Teff ratio (97). In murine breast can-
cer models, Huang et al. found that lower doses of anti-VEGFR2
antibody (DC101) therapy did not significantly change vessel
density in tumors, but induced vascular normalization, polar-
ized tumor-associated macrophages (TAMs) from an M2-like
(immunosuppressive) to an M1-like phenotype (immunostim-
ulatory), decreased myeloid-derived suppressor cells (MDSCs),
and significantly increased tumor-infiltrating CD4+ and CD8+
T cells. Indeed, when combined with a vaccine therapy, DC101
produced a CD8+ T-cell-dependent anti-tumor response (100).
In the same line of evidence, Shrimali et al. evaluated the syner-
gism of anti-angiogenic agents with adoptive cell transfer therapy
in a murine melanoma model, finding increased infiltration of
the adoptively transferred cells into the tumor in combination
with anti-VEGF therapy, and to a lesser extent when combined
with DC101 antibody (99). Additionally, in a murine model of
spontaneous pancreatic carcinoma (RIP1-Tag5), vessel normal-
ization by the deletion of Rgs5 (RIP1-Tag5XRgs5−/−) resulted in
increased immune effector cell infiltration into tumors and sub-
stantially prolonged survival after adoptive CD4+ and CD8+ T
cells transfer (98). The evidence that anti-angiogenic agents have
the potential to recondition the tumor immune microenviron-
ment toward a more immunosupportive profile (89) promotes
their combination with immunotherapy.
NOT ALL BLOOD VESSELS ARE BAD
The intra-tumoral development of high endothelium venules
(HEVs) and a variety of blood vessels could be considered a marker
of good prognosis, since HEV are considered the “gateways for
TILs” (101, 102). HEV are specialized post-capillary venules nor-
mally found in secondary lymphoid organs (with the exception of
spleen), where they support high levels of lymphocyte extrava-
sation from the blood into the lymph nodes (103, 104). The
endothelial HEV cells are cuboidal and plump, in contrast with
the flat cells of the vascular endothelium. HEV express 6-sulfosialyl
Lewis X ligands (L-selectin ligands) on their endoluminal surface,
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which are recognized by the HEV-specific antibody MECA-79
(105) and mediates the initial capture and rolling interactions of
lymphocytes along the vessel walls (103, 106). Therefore, the pres-
ence of a large number of lymphocytes attached to their walls is not
surprising (103). Although HEV are normally restricted to lymph
nodes, HEV-like structures are also found in chronically inflamed
non-lymphoid tissues in several inflammatory diseases, including
rheumatoid arthritis, inflammatory bowel disease, chronic gas-
tritis, and autoimmune thyroiditis (104, 107). In addition, in an
experimental vaccination system, HEV-like structures were found
in tertiary lymph node structures at vaccination sites with DC/Apo
B16 melanoma cells in the B16/BL6 system (108).
In the last years, the presence of HEV-like structures in tumors
was reported for the first time. MECA-79+ vessels were observed
by IHC in approximately 60–80% of human primary CM and
breast, ovary, lung, and colon carcinomas, but were not detected
in normal tissue distant from the tumor site (101). Furthermore,
HEV were also observed in human CM metastases (109, 110),
although the number of tumor HEV was lower than in pri-
mary CM (110). Although the impact of HEV in CM patients
is unknown, its occurrence within tumors could represent an
important prognostic biomarker. In a retrospective study, breast
cancer patients with high densities of tumor HEVs had signifi-
cantly longer metastasis-free, disease-free, and OS rates (101). In
concordance, tumor progression from breast carcinoma in situ to
invasive carcinoma was accompanied by a reduction in the density
of tumor HEVs (111). Interestingly, tumor areas with high HEV
density localize specifically with lymphocyte-rich tumor areas, as
is seen in lymph nodes. Furthermore, a strong correlation between
the density of tumor HEVs and the amount of tumor-infiltrating
CD3+T cells (mainly CD8+T cells) and CD20+B cells was found
in human breast carcinoma (101) and CM (102). T-lymphocytes
were frequently observed extravasating or attached to the lumi-
nal surface of tumor HEVs. This evidence strongly suggested that,
like HEV in lymph nodes, tumor HEV are actively involved in the
recruitment of TILs (101), which could lead to tumor suppression.
Nevertheless, tumor HEV could also present a gateway for Treg cell
entry into the tumor stroma. In breast cancer patients, a significant
increase in the density of tumor-infiltrating Treg cells and CD3+
cells was observed in HEV-high density tumors (111). In human
CM, the presence of tumor-infiltrating Treg cells seems to be inde-
pendent of HEV occurrence, since no significant difference in Treg
cell infiltration was observed between samples with low and high
HEV densities (102). The incidence of Treg cells in tumor HEVs
seems to be more complex; a better understanding of the mech-
anisms involving Treg cells and tumor HEVs is required, in order
to find new opportunities for more effective anti-tumor therapy.
COMBINATION THERAPIES
Considering the variety of immunosuppressive mechanisms, the
development of combined therapies could be key to enhancing
cancer immunotherapy.
Several clinical trials are evaluating the combination of anti-
angiogenic agents and immune checkpoint inhibitors. One eval-
uates the potential synergy between Ipilimumab and Beva-
cizumab, a VEGF inhibitor, in patients with Stage III/IV CM
(NCT01950390). Yuan et al. found that pre-treatment blood levels
of VEGF were associated with clinical response to Ipilimumab
(112). A phase I study (NCT00790010),comparing patients treated
with both drugs or Ipilimumab alone reported changes in the
intra-tumoral vascular endothelia and increased trafficking and
infiltration of immune cells (CD8+ T cells and CD163+ dendritic
macrophages) in tumors (113). There are also ongoing clinical
trials evaluating anti-angiogenic therapies combined with anti-
PD-1/PD-L1 therapies. A Phase Ib study is evaluating the safety
and preliminary efficacy of MPDL3280A (an engineered anti-PD-
L1 antibody) in combination with Bevacizumab (NCT01633970);
alternatively, the anti PD-1 mAb Nivolumab is being evaluated in
combination with Bevacizumab (NCT01454102) as maintenance
therapy.
Turning our attention to another important regulatory node,
indoleamine 2,3-dioxygenase (IDO) is an enzyme that catalyzes
the rate-limiting step in tryptophan degradation to kynurenine.
Since tryptophan is not synthesized by mammalian cells and is
an essential amino acid for lymphocytes, IDO overexpression
and subsequent tryptophan depletion has been proposed as an
immunosuppressive factor (114, 115). This phenomenon has been
reported in CM cells and in draining lymph nodes. IDO overex-
pression would correlate with tumor progression and invasiveness
(116–118). Pre-clinical studies demonstrated that CTLA-4 block-
ade synergizes with IDO inhibitors (119), indicating that IDO
could play a negative role in anti-CTLA-4 therapy.
Inducible T-cell costimulator (ICOS) is another combinatory
target molecule of interest. Expressed by activated T cells, ICOS
was identified as a component of the anti-tumoral effects of CTLA-
4 blockade (120) and its expression was increased in T cells of
treated patients. The combination of anti-CTLA-4 antibody and
ICOS activation, which was mediated by tumor vaccines engi-
neered to express the ICOS ligand, enhanced anti-tumor response
(121). Recently, Ng Tang et al. suggested that the frequency of
ICOS+CD4+ T cells can be used as a pharmacodynamic bio-
marker for anti-CTLA-4 therapy (122). They reported an increase
in ICOS+CD4+ T-cell frequency after anti-CTLA-4 treatment.
BIOMARKERS/GENE SIGNATURES
The identification of biomarkers associated with clinical response
to immunotherapy remains elusive. Several markers have been
proposed as indicators of Ipilimumab response. In CM, an increase
in the absolute lymphocyte count after two doses of Ipilimumab
was associated with clinical response (123). The presence of NY-
ESO-1-specific antibodies and CD8+ T cells also correlated with
clinical benefit (124). A recent study suggested that the frequency
of circulating MDSC correlated with a worst clinical outcome for
CM patients treated with Ipilimumab (125).
As previously discussed, PD-L1 expression, even in a small per-
centage of tumor cells, is postulated as a predictive marker for
anti-tumor response of anti-PD-1 and anti-PD-L1 treatment, but
evidence is not conclusive, since published results appear contra-
dictory. It could be assumed as an alternative that high-affinity
binding of the mAb to PD-1 would be sufficient to block the
negative loop that arrests CD8+ cell proliferation.
Gene expression signatures have been proposed as response
predictors for different types of immunotherapy. For exam-
ple, Harlin et al. performed a gene expression profiling of CM
Frontiers in Immunology | Immunotherapies and Vaccines March 2015 | Volume 6 | Article 127 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Madorsky Rowdo et al. Tumor and immunity combat
metastases and found two different tumor subsets that could be
correlated with the presence or absence of T cells. These observa-
tions could be explained by the fact that some tumors express
chemokines that mediate the recruitment of activated T cells
into metastatic sites, while others do not (126). The absence of
chemokine expression in some tumors could represent a barrier
to effective immunotherapy, since those tumors would not attract
lymphocytes.
Recently, Carretero et al. have shown that, in patients under-
going various forms of immunotherapy, some lesions regress
whereas others progress (127). When lesions from the same
patient were submitted to genomic analysis, they reported that
regression was accompanied by high expression of HLA-I mole-
cules, whereas progressing lesions had lost the HLA-I-presentation
genes. Regressions were acute-type rejection, and were accompa-
nied by the expression of genes involved in IFN-mediated antigen
presentation and IFN-mediated response (STAT-1/IRF1).
CONCLUSION
Recent years have seen dramatic advances that demonstrate the
power of the immune system to attack tumors, if the adequate
brakes are released. However, several challenges remain. A primary
challenge is to establish whether Teff lymphocytes are directed to
normal tumor-associated antigens, oncofetal antigens, or neoanti-
gens. Another challenge is to establish a method to increase the
number of “dormant” lymphocytes, which, in spite of displaying
the adequate TCR, must have their brakes released. A third chal-
lenge is to create strategies to increase the ingress of lymphocytes
into tumors. Vaccines may be adequate for this purpose, since they
could be used in an adjuvant setting, at a time in which metastases
have not built a superstructure with many immunosuppressive
obstacles to overcome. Finally, it is well established that patches of
tumor cells with down-regulated HLA-I expression are found in
many tumors, including CM. Perhaps, this is one of the reasons
why the number of patients who attain CR with mAbs aiming to
CD8+ cell activation is still low. It is likely that the activation of
NK cell circuitry would be necessary to effectively target HLA-I−
tumor cells.
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